Addressing Safety Concerns in the Treatment of Atopic Dermatitis(Accreditation Expired) Faculty: Jon Hanifin, MD | Mark Boguniewicz, MD | Adelaide Hebert, MD | Jonathan Spergel, MD, PhD CME / CE credit hour: 1.0 In this CME activity, four distinguished members of the medical community review and discuss current clinical trial data focusing on safety issues surrounding the use of topical corticosteroid and TCIs. Panel members review the potential short- and long-term adverse effects of each drug class and then place this information into context by evaluating the risk-benefit ratio associated with each treatment.
The Conundrum of Rash in Management of EGFR Inhibitors(Accreditation Expired) Faculty: Roy S. Herbst, MD, PhD | Mario Lacouture, MD | Roman Perez-Soler, MD | Sandy Kurtin, RN, MS, AOCN®, NP CME / CE credit hour: 1.0 New therapies targeting the epidermal growth factor receptor (EGFR) have been used in the treatment of a variety of cancers. Although generally well tolerated, EGFR inhibitors are associated with the development of dermatologic reactions (e.g., papulopustular rash, xerosis, pruritus, periungual inflammation, and alopecia) in most patients. At present, little is known about the etiology of these reactions, and no evidence-based management guidelines have been set forth in the dermatologic literature.
All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.
